Performance of Ultrasound in the Diagnosis of Gout in a Multicenter Study: Comparison With Monosodium Urate Monohydrate Crystal Analysis as the Gold Standard

Objective To examine the performance of ultrasound (US) for the diagnosis of gout using the presence of monosodium urate monohydrate (MSU) crystals as the gold standard. Methods We analyzed data from the Study for Updated Gout Classification Criteria (SUGAR), a large, multicenter observational cross...

Full description

Saved in:
Bibliographic Details
Published inArthritis & rheumatology (Hoboken, N.J.) Vol. 69; no. 2; pp. 429 - 438
Main Authors Ogdie, Alexis, Taylor, William J., Neogi, Tuhina, Fransen, Jaap, Jansen, Tim L., Schumacher, H. Ralph, Louthrenoo, Worawit, Vazquez‐Mellado, Janitzia, Eliseev, Maxim, McCarthy, Geraldine, Stamp, Lisa K., Perez‐Ruiz, Fernando, Sivera, Francisca, Ea, Hang‐Korng, Gerritsen, Martijn, Cagnotto, Giovanni, Cavagna, Lorenzo, Lin, Chingtsai, Chou, Yin‐Yi, Tausche, Anne‐Kathrin, Lima Gomes Ochtrop, Manuella, Janssen, Matthijs, Chen, Jiunn‐Horng, Slot, Ole, Lazovskis, Juris, White, Douglas, Cimmino, Marco A., Uhlig, Till, Dalbeth, Nicola
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.02.2017
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Objective To examine the performance of ultrasound (US) for the diagnosis of gout using the presence of monosodium urate monohydrate (MSU) crystals as the gold standard. Methods We analyzed data from the Study for Updated Gout Classification Criteria (SUGAR), a large, multicenter observational cross‐sectional study of consecutive subjects with at least 1 swollen joint who conceivably may have gout. All subjects underwent arthrocentesis; cases were subjects with confirmed MSU crystals. Rheumatologists or radiologists who were blinded with regard to the results of the MSU crystal analysis performed US on 1 or more clinically affected joints. US findings of interest were double contour sign, tophus, and snowstorm appearance. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated. Multivariable logistic regression models were used to examine factors associated with positive US results among subjects with gout. Results US was performed in 824 subjects (416 cases and 408 controls). The sensitivity, specificity, PPV, and NPV for the presence of any 1 of the features were 76.9%, 84.3%, 83.3%, and 78.2%, respectively. Sensitivity was higher among subjects with a disease duration of ≥2 years and among subjects with subcutaneous nodules on examination (suspected tophus). Associations with a positive US finding included suspected clinical tophus (odds ratio [OR] 4.77 [95% confidence interval (95% CI) 2.23–10.21]), any abnormality on plain radiography (OR 4.68 [95% CI 2.68–8.17]), and serum urate level (OR 1.31 [95% CI 1.06–1.62]). Conclusion US features of MSU crystal deposition had high specificity and high PPV but more limited sensitivity for early gout. The specificity remained high in subjects with early disease and without clinical signs of tophi.
Bibliography:Dr. Taylor has received consulting fees from AstraZeneca and Pfizer (less than $10,000 each).
Dr. Dalbeth has received consulting fees and/or speaking fees from Takeda, Pfizer, Crealta, CymaBay, and Ardea/AstraZeneca (less than $10,000 each) and institutional grants from Ardea/AstraZeneca.
Dr. Cimmino has received speaking fees (less than $10,000) and grants from Menarini.
Dr. Perez‐Ruiz has received consulting fees from AstraZeneca, Menarini, and CymaBay (more than $10,000 each) and speaking fees from AstraZeneca and Menarini (more than $10,000 each).
Dr. Ogdie has received consulting fees from Novartis (less than $10,000).
Dr. McCarthy has received consulting fees and speaking fees from Menarini (less than $10,000).
Dr. Tausche has received consulting fees, speaking fees, and/or honoraria from Berlin‐Chemie Menarini, Andrea Biosciences/AstraZeneca, and Novartis (less than $10,000 each).
Dr. Stamp has received consulting fees from AstraZeneca (less than $10,000).
Supported by the American College of Rheumatology (Classification Criteria grant), the European League Against Rheumatism (Classification Criteria grant), Arthritis New Zealand, Association Rhumatisme et Travail, and Asociación de Reumatólogos del Hospital de Cruces. Dr. Ogdie's work was supported by the NIH (National Institute of Arthritis and Musculoskeletal and Skin Diseases grant K23‐AR‐063764). Dr. Taylor's work was supported by Arthritis New Zealand. Dr. Neogi's work was supported by the NIH (grants P60‐AR‐47785 and R01‐AR‐062506). Dr. Dalbeth's work was supported by the Health Research Council of New Zealand.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ISSN:2326-5191
2326-5205
DOI:10.1002/art.39959